Brief: Celyad Oncology Announces First Patient Dosed In Keynote-B79 Phase 1B Trial

Celyad Oncology SA

16/12/2021 06:04

Dec 16 (Reuters) - Celyad Oncology SA  CYAD.BR :
    * CELYAD ONCOLOGY ANNOUNCES FIRST PATIENT DOSED IN
KEYNOTE-B79
PHASE 1B TRIAL
    * KEYNOTE-B79 PHASE 1B TRIAL WILL EVALUATE CYAD-101 AND
KEYTRUDA®
(PEMBROLIZUMAB) IN PATIENTS WITH MICROSATELLITE STABLE (MSS)
METASTATIC COLORECTAL CANCER (MCRC)
    * ASCO-GI CONFERENCE ABSTRACT ACCEPTED THAT HIGHLIGHTS
KEYNOTE-B79
CLINICAL TRIAL DESIGN

Source text for Eikon:  ID:nGNX572NnD 
Further company coverage:  CYAD.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))